Название продукции:Methanesulfonic acid, 1,1,1-trifluoro-, 1-cyclopenten-1-yl ester
IUPAC Name:cyclopent-1-en-1-yl trifluoromethanesulfonate
- CAS:28075-49-2
- Молекулярная формула:C6H7F3O3S
- Чистота:95%
- Номер в каталоге:CM1079451
- Молекулярная масса:216.17
Упаковочная единица |
Доступно для заказа |
Цена ($) |
Количество |
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:28075-49-2
- Молекулярная формула:C6H7F3O3S
- Точка плавления:-
- Smiles-код:O=S(=O)(OC1=CCCC1)C(F)(F)F
- Плотность:
- Номер в каталоге:CM1079451
- Молекулярная масса:216.17
- Точка кипения:
- Номер Mdl:
- Хранение:
Category Infos
- Cyclopentanes
- Cyclopentane is a cycloalkane, an organic compound with a molecular formula of C5H10, a colorless and transparent liquid, insoluble in water, soluble in most organic solvents such as ethanol, ether, benzene, carbon tetrachloride, acetone, etc. It is mainly used as a solvent and chromatographic reference materials.
- Cyclopentanes,where to buy Cyclopentanes
- Cyclopentanes
- Cyclopentane (also called C pentane) is a highly flammable alicyclic hydrocarbon with chemical formula C5H10 and CAS number 287-92-3, consisting of a ring of five carbon atoms each bonded with two hydrogen atoms above and below the plane. It occurs as a colorless liquid with a petrol-like odor.
Column Infos
- Zetomipzomib
- Kezar Life Sciences announces clinical hold of Zetomipzomib IND for treatment of lupus nephritis(LN). Zetomipzomib (KZR-616) is a selective inhibitor of the immunoproteasome currently undergoing clinical investigation in autoimmune disorders.
LN is a disease comprising a spectrum of vascular, glomerular and tubulointerstitial lesions and develops in approximately 50% of SLE patients within 10 years of their initial diagnosis. LN is associated with considerable morbidity, including an increased risk of end-stage renal disease requiring dialysis or renal transplantation and an increased risk of death. There are limited approved therapies for the treatment of LN. Management typically consists of induction therapy to achieve remission and long-term maintenance therapy to prevent relapse.